3 Tesla magnetic resonance imaging with and without corticotropin releasing hormone stimulation for the detection of microadenomas in Cushing's syndrome

Clin Endocrinol (Oxf). 2010 Jun;72(6):793-9. doi: 10.1111/j.1365-2265.2009.03723.x. Epub 2009 Oct 7.

Abstract

Objective: We sought to determine if higher resolution 3 Tesla (T) magnetic resonance imaging (MRI) with or without ovine corticotropin releasing hormone (o-CRH) stimulation would increase the sensitivity for detection of pituitary microadenomas in ACTH-dependent Cushing's syndrome (CS).

Design and patients: We prospectively identified 23 patients over a 2-year period with clinical and biochemical evidence of ACTH-dependent CS with no lesion (n = 11) or equivocal lesion (n = 10) on 1.5T MRI. Subsequently, two additional MRIs were performed in random order: 3T nonstimulated MRI or 3T MRI with o-CRH in all patients. Three neuroradiologists reviewed all examinations in a randomized blinded fashion. Patients were divided into four groups, depending on the outcome of their evaluation and treatment for CS. Two patients had to be excluded, and so we report on 21 subjects.

Measurements and results: Both 3T MRI without (P < 0.016) and with o-CRH stimulation (P < 0.013) was significantly more sensitive for detection of pituitary microadenomas than 1.5T MRI for Group 1 (definitive proof of Cushing's disease, n = 10). Group 2 (those in group 1, plus three patients where dynamic/invasive testing suggested pituitary source) also showed a significant (P < 0.012) advantage for 3T. There was no difference between the 3T and the 3T o-CRH examinations for any of the pulse sequences. We did not observe a statistically significant difference in other patient groups [patients with recurrent CD (n = 6) and patients with ectopic CS (n = 2)].

Conclusions: The results of our prospective blinded studies suggest that 3T MRI of pituitary gland should be considered in evaluation of patients with ACTH-dependent CD when 1.5T imaging is negative or equivocal.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • ACTH-Secreting Pituitary Adenoma / diagnostic imaging*
  • ACTH-Secreting Pituitary Adenoma / pathology
  • Adenoma / diagnostic imaging*
  • Adenoma / pathology
  • Adult
  • Aged
  • Corticotropin-Releasing Hormone / pharmacology
  • Corticotropin-Releasing Hormone / therapeutic use*
  • Cushing Syndrome / diagnostic imaging*
  • Diagnostic Techniques, Endocrine
  • Female
  • Humans
  • Magnetic Resonance Imaging / methods*
  • Male
  • Middle Aged
  • Radiography
  • Sensitivity and Specificity
  • Single-Blind Method
  • Stimulation, Chemical
  • Tumor Burden / drug effects
  • Tumor Burden / physiology
  • Young Adult

Substances

  • Corticotropin-Releasing Hormone